Guobang Pharma Ltd. (SHA:605507)
China flag China · Delayed Price · Currency is CNY
15.58
+0.19 (1.23%)
Sep 4, 2026, 3:00 PM CST

Guobang Pharma Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
706.6820.82781.6612.46920.9706.03
Depreciation & Amortization
487.37476.96433.38321.14260.29201.12
Other Amortization
1.441.130.571.241.51.18
Loss (Gain) From Sale of Assets
-25.27-24.819.11-0.05-0.3
Asset Writedown & Restructuring Costs
8.117.676.545.0815.8461.14
Loss (Gain) From Sale of Investments
-31.78-29.58-27.64-23.56-24.09-10.53
Provision & Write-off of Bad Debts
2.25.6512.07-7.1711.720.92
Other Operating Activities
63.8447.2225.4843.289.4433.35
Change in Accounts Receivable
302.08258.28-634.31-929.35-255.53-841.81
Change in Inventory
-409.23-439.76-20.689.2-127.53-371.61
Change in Accounts Payable
-189.35-562.84120.73488.71179.6948.23
Change in Other Net Operating Assets
4.56.354.87-2.474.561.62
Operating Cash Flow
911.35559.28706.41516.761,017-176.18
Operating Cash Flow Growth
-13.96%-20.83%36.70%-49.19%--

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-448.84-277.71-419.12-748.44-803.12-448.04
Sale of Property, Plant & Equipment
24.124.117.9624.917.814.34
Investment in Securities
-354.16-597.85-112.68362.07373.54-1,252
Other Investing Activities
3.83---05.65
Investing Cash Flow
-775.08-851.46-513.85-361.47-411.76-1,690

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
---11-
Long-Term Debt Issued
-1,032593.21964778.11364.43
Total Debt Issued
670.981,032593.21965779.11364.43
Short-Term Debt Repaid
----1-1-
Long-Term Debt Repaid
--813.79-782.29-656.5-283-1,115
Total Debt Repaid
-585.45-813.79-782.29-657.5-284-1,115
Net Debt Issued (Repaid)
85.53218.24-189.08307.5495.11-750.3
Issuance of Common Stock
184.58184.5897.11--2,677
Repurchase of Common Stock
-216.39-166.14-101.01---
Common Dividends Paid
-354.78-359.63-194.1-361.64-128.21-333.74
Other Financing Activities
--0.588.20.05-22.18
Financing Cash Flow
-301.06-122.95-386.49-45.94366.951,571

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-24.83-1.3627.0810.7135.27-9.93
Net Cash Flow
-189.62-416.49-166.85120.071,007-305.43

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
462.51281.57287.29-231.68213.92-624.23
Free Cash Flow Growth
-29.45%-1.99%----
Free Cash Flow Margin
7.55%4.68%4.88%-4.33%3.74%-13.86%
Free Cash Flow Per Share
0.600.360.37-0.300.27-0.87
Levered Free Cash Flow
515.37171.7448.34134.75340.79-852.93
Unlevered Free Cash Flow
529.89186.6965.39148.86351.13-834.98

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Income Tax Paid
30.9361.7648.15-100.8531.6136.92
Change in Working Capital
-301.17-745.78-534.69-435.71-178.6-1,169